Start Your Search
Poster Display session (Friday) (ID 65)
- Event: ELCC 2018
- Type: Poster Display session
- Presentations: 1
- Coordinates: 4/13/2018, 12:30 - 13:00, Hall 1
151P - Maintenance therapy using tyrosine kinase inhibitor (erlotinib) or pemetrexed in metastatic/locally advanced in EGFR mutation-negative lung cancer: Comparison of results (ID 522)
12:30 - 13:00 | Author(s): A. Janu
Maintenance therapy of locally advanced or metatstatic non-small cell lung cancer (NSCLC) other than predominantly squamous cell histology in patients whose disease has not progressed following 4 to 6 cycles of platinum-based doublet therapy has been standard of care. Pemetrexed or Tyrosine Kinase Inhibitors like Erlotinib have both been used as either continuous maintenance or switch maintenance therapy.
All patients of NSCLC other than the Squamous Cell carcinoma who have completed either 4 or 6 cycles of platinum and pemetrexed and have either CR/PR/SD on response assessment scan post induction treatment and willing to participate in the study were randomized to receive either pemetrexed or TKI- Erlotinib. Patients were followed up till death. PS and OS were calculated for each arm and indirectly compared.
Two hundred patients were randomized to receive either pemetrexed or erlotinib fron November 2014 to March 2017. Median age of cohort was 55(28–79). Of the 200 patients, 132 patients were male and 68 were female. PS was 0–1 in 195 patients. Smokers constituted 63% (126/200). Majority of patients had stable disease (62.5%), post completion of induction chemotherapy (125/200). Median number of cycles was 4 (4–6). Median PFS in Pemetrexed arm was 4.46 month (95%CI; 3.98 to 4.95), while in Erlotinib arm the median PFS was 4.5 month (95% CI; 3.98 to 4.95) (Hazard ratio = 0.98; 95% CI, 0.714 to 1.369, p-value 0.945). Median OS from starting induction therapy was 16.6 months (15.2–17.9 months) in Pemetrexed arm versus 18.3 months (95% CI 13.75–22.91 months) in Erlotinib arm (p-0.321). [HR = 1.222 (95% CI 0.821–1.818)].
On indirect comparison, maintenance treatment with Pemetrexed and Erlotinib has similar PFS and OS.
Clinical trial identification:
Legal entity responsible for the study:
Tata Memorial Hospital Centre, Mumbai, India
Has not received any funding
All authors have declared no conflicts of interest.